血清 ADAM 金属肽酶结构域 12 作为一种有前途的乳腺癌和肝癌诊断生物标志物。

Serum ADAM metallopeptidase domain 12 as a promising diagnostic biomarker for breast and liver cancer.

机构信息

Department of Medical Laboratory, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China.

Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, Guangzhou, 510632, China.

出版信息

Clin Transl Oncol. 2023 Feb;25(2):473-481. doi: 10.1007/s12094-022-02960-2. Epub 2022 Oct 2.

DOI:10.1007/s12094-022-02960-2

PMID:36183312

Abstract

BACKGROUND

ADAM metallopeptidase domain 12 (ADAM12) is generally upregulated in tissues of various tumors, emerging as a prognostic biomarker. However, the clinical significance of serum ADAM12 in tumors still remains to be fully elucidated. The present study aimed to investigate the expression and prognostic value of serum ADAM12 in tumor patients.

MATERIALS AND METHODS

Serum samples were collected from healthy doners (HDs; n = 87) and patients (n = 238) with a clinical diagnosis of breast, liver, lung, stomach and esophageal (STES) and thyroid cancer. Serum ADAM12 protein and mRNA expression was detected by enzyme-linked immunosorbent assay (ELISA) and reverse transcription polymerase chain reaction (RT-PCR), respectively. Receiver-operator characteristic (ROC) analysis was performed to explored the prognostic value of serum ADAM12 expression.

RESULTS

The expression of serum ADAM12 in breast and liver cancer patients was significantly upregulated compared with HDs. In patients with breast cancer, the levels of serum ADAM12 protein and mRNA were significantly higher in tumor stages than that in HDs (p < 0.05), with AUC value of 0.82. In liver cancer, elevated levels of serum ADAM12 protein were significantly correlated with clinical stage (r = 0.74; p = 6.9e-4) and T stage (r = 0.74, p = 7.6e-4), and attained AUC value of 1. However, the clinical significance of serum ADAM12 expression in lung, STES and thyroid cancer had not been found.

CONCLUSIONS

Serum ADAM12 expression showed high degree of tumor heterogeneity, and may be a valuable noninvasive diagnostic and prognostic biomarker for breast and liver cancer.

摘要

背景

解整合素金属蛋白酶 12（ADAM12）在多种肿瘤组织中普遍上调，成为一种预后生物标志物。然而，血清 ADAM12 在肿瘤中的临床意义仍有待充分阐明。本研究旨在探讨肿瘤患者血清 ADAM12 的表达及其预后价值。

材料与方法

收集 87 例健康供者（HDs）和 238 例临床诊断为乳腺癌、肝癌、肺癌、胃癌和食管癌（STES）及甲状腺癌患者的血清样本。采用酶联免疫吸附试验（ELISA）和逆转录聚合酶链反应（RT-PCR）分别检测血清 ADAM12 蛋白和 mRNA 的表达。采用受试者工作特征（ROC）曲线分析血清 ADAM12 表达的预后价值。

结果

与 HDs 相比，乳腺癌和肝癌患者血清 ADAM12 的表达明显上调。在乳腺癌患者中，肿瘤期血清 ADAM12 蛋白和 mRNA 的水平明显高于 HDs（p<0.05），AUC 值为 0.82。在肝癌中，血清 ADAM12 蛋白水平升高与临床分期（r=0.74;p=6.9e-4）和 T 分期（r=0.74;p=7.6e-4）显著相关，AUC 值为 1。然而，在肺癌、STES 和甲状腺癌中，血清 ADAM12 表达的临床意义尚未发现。